Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin
There is an urgent need to develop non-invasive pharmacodynamic endpoints for the evaluation of new molecular therapeutics that inhibit signal transduction. We hypothesised that, when labelled appropriately, changes in choline kinetics could be used to assess geldanamycin pharmacodynamics, which inv...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2002-09, Vol.87 (7), p.783-789 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 789 |
|---|---|
| container_issue | 7 |
| container_start_page | 783 |
| container_title | British journal of cancer |
| container_volume | 87 |
| creator | Liu, D Hutchinson, O C Osman, S Price, P Workman, P Aboagye, E O |
| description | There is an urgent need to develop non-invasive pharmacodynamic endpoints for the evaluation of new molecular therapeutics that inhibit signal transduction. We hypothesised that, when labelled appropriately, changes in choline kinetics could be used to assess geldanamycin pharmacodynamics, which involves inhibition of the HSP90 molecular chaperone→Raf1→Mitogenic Extracellular Kinase→Extracellular Signal-Regulated Kinase 1 and 2 signal transduction pathway. Towards identifying a potential pharmacodynamic marker response, we have studied radiolabelled choline metabolism in HT29 human colon carcinoma cells following treatment with geldanamycin. We studied the effects of geldanamycin, on net cellular accumulation of (methyl-
14
C)choline and (methyl-
14
C)phosphocholine production. In parallel experiments, the effects of geldanamycin on extracellular signal-regulated kinase 1 and 2 phosphorylation and cell viability were also assessed. Additional validation studies were carried out with the mitogenic extracellular kinase inhibitor U0126 as a positive control; a cyclin-dependent kinase-2 inhibitor roscovitine and the phosphatidylinositol 3-kinase inhibitor LY294002 as negative controls. Hemicholinium-3, an inhibitor of choline transport and choline kinase activity was included as an additional control. In exponentially growing HT29 cells, geldanamycin inhibited extracellular signal-regulated kinase 1 and 2 phosphorylation in a concentration- and time-dependent manner. These changes were associated with a reduction in (methyl-
14
C)choline uptake, (methyl-
14
C) phosphocholine production and cell viability. Brief exposure to U0126, suppressed phosphocholine production to the same extent as Hemicholinium-3. In contrast to geldanamycin and U0126, which act upstream of extracellular signal-regulated kinase 1 and 2, roscovitine and LY294002 failed to suppress phosphocholine production. Our results suggest that when labelled with carbon-11 isotope, (methyl-
11
C)choline may be a useful pharmacodynamic marker for the non-invasive evaluation of geldanamycin analogues. |
| doi_str_mv | 10.1038/sj.bjc.6600558 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2364261</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>998023511</sourcerecordid><originalsourceid>FETCH-LOGICAL-c541t-602dcdfd281f083bba2f01d09a2fb5925d10c551ed2503cdb6af7005ebc6b7f53</originalsourceid><addsrcrecordid>eNp1kc1rGzEQxUVoSJyPa28tove1R1pLu74USmiTQiCX-Cz06dVmLbnSbsD_fRXsJO0hugzi_ebNDA-hzwTmBOp2kfu56vWccwDG2hM0I6ymFWlp8wnNAKCpYEXhHF3k3JfvCtrmDJ0TSmva8OUMPa2zxdHhJI2Pg1R2GKzBuouDDxbLjCXedTJtpY5mH-TWa7yV6ckm7GLCY2dx9psgBzwmGbKZ9OhjwD50XvmxEBs7GFn69tqHK3Tq5JDt9bFeovWvn483d9X9w-3vmx_3lWZLMlYcqNHGGdoSB22tlKQOiIFVqYqtKDMENGPEGsqg1kZx6ZpyvlWaq8ax-hJ9P_juJrW1RttQlhvELvmy-l5E6cX_SvCd2MRnQWu-pJwUg29HgxT_TDaPoo9TKlfmgsDLY7xA8wOkU8w5Wfc2gIB4yUbkXpRsxDGb0vD137Xe8WMYBVgcgFyksLHpfeyHll8OHUGOU7Jvlq_6XwsOqAk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230000056</pqid></control><display><type>article</type><title>Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Liu, D ; Hutchinson, O C ; Osman, S ; Price, P ; Workman, P ; Aboagye, E O</creator><creatorcontrib>Liu, D ; Hutchinson, O C ; Osman, S ; Price, P ; Workman, P ; Aboagye, E O</creatorcontrib><description>There is an urgent need to develop non-invasive pharmacodynamic endpoints for the evaluation of new molecular therapeutics that inhibit signal transduction. We hypothesised that, when labelled appropriately, changes in choline kinetics could be used to assess geldanamycin pharmacodynamics, which involves inhibition of the HSP90 molecular chaperone→Raf1→Mitogenic Extracellular Kinase→Extracellular Signal-Regulated Kinase 1 and 2 signal transduction pathway. Towards identifying a potential pharmacodynamic marker response, we have studied radiolabelled choline metabolism in HT29 human colon carcinoma cells following treatment with geldanamycin. We studied the effects of geldanamycin, on net cellular accumulation of (methyl-
14
C)choline and (methyl-
14
C)phosphocholine production. In parallel experiments, the effects of geldanamycin on extracellular signal-regulated kinase 1 and 2 phosphorylation and cell viability were also assessed. Additional validation studies were carried out with the mitogenic extracellular kinase inhibitor U0126 as a positive control; a cyclin-dependent kinase-2 inhibitor roscovitine and the phosphatidylinositol 3-kinase inhibitor LY294002 as negative controls. Hemicholinium-3, an inhibitor of choline transport and choline kinase activity was included as an additional control. In exponentially growing HT29 cells, geldanamycin inhibited extracellular signal-regulated kinase 1 and 2 phosphorylation in a concentration- and time-dependent manner. These changes were associated with a reduction in (methyl-
14
C)choline uptake, (methyl-
14
C) phosphocholine production and cell viability. Brief exposure to U0126, suppressed phosphocholine production to the same extent as Hemicholinium-3. In contrast to geldanamycin and U0126, which act upstream of extracellular signal-regulated kinase 1 and 2, roscovitine and LY294002 failed to suppress phosphocholine production. Our results suggest that when labelled with carbon-11 isotope, (methyl-
11
C)choline may be a useful pharmacodynamic marker for the non-invasive evaluation of geldanamycin analogues.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6600558</identifier><identifier>PMID: 12232764</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Benzoquinones ; Biomedical and Life Sciences ; Biomedicine ; Blotting, Western ; Cancer Research ; Carbon Radioisotopes ; Cell Division - drug effects ; Cell growth ; Cell Survival - drug effects ; Choline - analogs & derivatives ; Choline - metabolism ; Choline - pharmacokinetics ; Cyclin-dependent kinases ; Drug Resistance ; Epidemiology ; Experimental Therapeutics ; Humans ; Kinases ; Lactams, Macrocyclic ; MAP Kinase Signaling System - drug effects ; Medical research ; Mitogen-Activated Protein Kinases - antagonists & inhibitors ; Mitogen-Activated Protein Kinases - metabolism ; Molecular Medicine ; Oncology ; Pharmacodynamics ; Phosphorylation ; Phosphorylation - drug effects ; Phosphorylcholine - metabolism ; Proteins ; Quinones - pharmacology ; Signal transduction ; Tumor Cells, Cultured</subject><ispartof>British journal of cancer, 2002-09, Vol.87 (7), p.783-789</ispartof><rights>The Author(s) 2002</rights><rights>Copyright Nature Publishing Group Sep 23, 2002</rights><rights>Copyright © 2002 Cancer Research UK 2002 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c541t-602dcdfd281f083bba2f01d09a2fb5925d10c551ed2503cdb6af7005ebc6b7f53</citedby><cites>FETCH-LOGICAL-c541t-602dcdfd281f083bba2f01d09a2fb5925d10c551ed2503cdb6af7005ebc6b7f53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364261/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364261/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,2727,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12232764$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, D</creatorcontrib><creatorcontrib>Hutchinson, O C</creatorcontrib><creatorcontrib>Osman, S</creatorcontrib><creatorcontrib>Price, P</creatorcontrib><creatorcontrib>Workman, P</creatorcontrib><creatorcontrib>Aboagye, E O</creatorcontrib><title>Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>There is an urgent need to develop non-invasive pharmacodynamic endpoints for the evaluation of new molecular therapeutics that inhibit signal transduction. We hypothesised that, when labelled appropriately, changes in choline kinetics could be used to assess geldanamycin pharmacodynamics, which involves inhibition of the HSP90 molecular chaperone→Raf1→Mitogenic Extracellular Kinase→Extracellular Signal-Regulated Kinase 1 and 2 signal transduction pathway. Towards identifying a potential pharmacodynamic marker response, we have studied radiolabelled choline metabolism in HT29 human colon carcinoma cells following treatment with geldanamycin. We studied the effects of geldanamycin, on net cellular accumulation of (methyl-
14
C)choline and (methyl-
14
C)phosphocholine production. In parallel experiments, the effects of geldanamycin on extracellular signal-regulated kinase 1 and 2 phosphorylation and cell viability were also assessed. Additional validation studies were carried out with the mitogenic extracellular kinase inhibitor U0126 as a positive control; a cyclin-dependent kinase-2 inhibitor roscovitine and the phosphatidylinositol 3-kinase inhibitor LY294002 as negative controls. Hemicholinium-3, an inhibitor of choline transport and choline kinase activity was included as an additional control. In exponentially growing HT29 cells, geldanamycin inhibited extracellular signal-regulated kinase 1 and 2 phosphorylation in a concentration- and time-dependent manner. These changes were associated with a reduction in (methyl-
14
C)choline uptake, (methyl-
14
C) phosphocholine production and cell viability. Brief exposure to U0126, suppressed phosphocholine production to the same extent as Hemicholinium-3. In contrast to geldanamycin and U0126, which act upstream of extracellular signal-regulated kinase 1 and 2, roscovitine and LY294002 failed to suppress phosphocholine production. Our results suggest that when labelled with carbon-11 isotope, (methyl-
11
C)choline may be a useful pharmacodynamic marker for the non-invasive evaluation of geldanamycin analogues.</description><subject>Benzoquinones</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Blotting, Western</subject><subject>Cancer Research</subject><subject>Carbon Radioisotopes</subject><subject>Cell Division - drug effects</subject><subject>Cell growth</subject><subject>Cell Survival - drug effects</subject><subject>Choline - analogs & derivatives</subject><subject>Choline - metabolism</subject><subject>Choline - pharmacokinetics</subject><subject>Cyclin-dependent kinases</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Experimental Therapeutics</subject><subject>Humans</subject><subject>Kinases</subject><subject>Lactams, Macrocyclic</subject><subject>MAP Kinase Signaling System - drug effects</subject><subject>Medical research</subject><subject>Mitogen-Activated Protein Kinases - antagonists & inhibitors</subject><subject>Mitogen-Activated Protein Kinases - metabolism</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Pharmacodynamics</subject><subject>Phosphorylation</subject><subject>Phosphorylation - drug effects</subject><subject>Phosphorylcholine - metabolism</subject><subject>Proteins</subject><subject>Quinones - pharmacology</subject><subject>Signal transduction</subject><subject>Tumor Cells, Cultured</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kc1rGzEQxUVoSJyPa28tove1R1pLu74USmiTQiCX-Cz06dVmLbnSbsD_fRXsJO0hugzi_ebNDA-hzwTmBOp2kfu56vWccwDG2hM0I6ymFWlp8wnNAKCpYEXhHF3k3JfvCtrmDJ0TSmva8OUMPa2zxdHhJI2Pg1R2GKzBuouDDxbLjCXedTJtpY5mH-TWa7yV6ckm7GLCY2dx9psgBzwmGbKZ9OhjwD50XvmxEBs7GFn69tqHK3Tq5JDt9bFeovWvn483d9X9w-3vmx_3lWZLMlYcqNHGGdoSB22tlKQOiIFVqYqtKDMENGPEGsqg1kZx6ZpyvlWaq8ax-hJ9P_juJrW1RttQlhvELvmy-l5E6cX_SvCd2MRnQWu-pJwUg29HgxT_TDaPoo9TKlfmgsDLY7xA8wOkU8w5Wfc2gIB4yUbkXpRsxDGb0vD137Xe8WMYBVgcgFyksLHpfeyHll8OHUGOU7Jvlq_6XwsOqAk</recordid><startdate>20020923</startdate><enddate>20020923</enddate><creator>Liu, D</creator><creator>Hutchinson, O C</creator><creator>Osman, S</creator><creator>Price, P</creator><creator>Workman, P</creator><creator>Aboagye, E O</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20020923</creationdate><title>Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin</title><author>Liu, D ; Hutchinson, O C ; Osman, S ; Price, P ; Workman, P ; Aboagye, E O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c541t-602dcdfd281f083bba2f01d09a2fb5925d10c551ed2503cdb6af7005ebc6b7f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Benzoquinones</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Blotting, Western</topic><topic>Cancer Research</topic><topic>Carbon Radioisotopes</topic><topic>Cell Division - drug effects</topic><topic>Cell growth</topic><topic>Cell Survival - drug effects</topic><topic>Choline - analogs & derivatives</topic><topic>Choline - metabolism</topic><topic>Choline - pharmacokinetics</topic><topic>Cyclin-dependent kinases</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Experimental Therapeutics</topic><topic>Humans</topic><topic>Kinases</topic><topic>Lactams, Macrocyclic</topic><topic>MAP Kinase Signaling System - drug effects</topic><topic>Medical research</topic><topic>Mitogen-Activated Protein Kinases - antagonists & inhibitors</topic><topic>Mitogen-Activated Protein Kinases - metabolism</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Pharmacodynamics</topic><topic>Phosphorylation</topic><topic>Phosphorylation - drug effects</topic><topic>Phosphorylcholine - metabolism</topic><topic>Proteins</topic><topic>Quinones - pharmacology</topic><topic>Signal transduction</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, D</creatorcontrib><creatorcontrib>Hutchinson, O C</creatorcontrib><creatorcontrib>Osman, S</creatorcontrib><creatorcontrib>Price, P</creatorcontrib><creatorcontrib>Workman, P</creatorcontrib><creatorcontrib>Aboagye, E O</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, D</au><au>Hutchinson, O C</au><au>Osman, S</au><au>Price, P</au><au>Workman, P</au><au>Aboagye, E O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2002-09-23</date><risdate>2002</risdate><volume>87</volume><issue>7</issue><spage>783</spage><epage>789</epage><pages>783-789</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>There is an urgent need to develop non-invasive pharmacodynamic endpoints for the evaluation of new molecular therapeutics that inhibit signal transduction. We hypothesised that, when labelled appropriately, changes in choline kinetics could be used to assess geldanamycin pharmacodynamics, which involves inhibition of the HSP90 molecular chaperone→Raf1→Mitogenic Extracellular Kinase→Extracellular Signal-Regulated Kinase 1 and 2 signal transduction pathway. Towards identifying a potential pharmacodynamic marker response, we have studied radiolabelled choline metabolism in HT29 human colon carcinoma cells following treatment with geldanamycin. We studied the effects of geldanamycin, on net cellular accumulation of (methyl-
14
C)choline and (methyl-
14
C)phosphocholine production. In parallel experiments, the effects of geldanamycin on extracellular signal-regulated kinase 1 and 2 phosphorylation and cell viability were also assessed. Additional validation studies were carried out with the mitogenic extracellular kinase inhibitor U0126 as a positive control; a cyclin-dependent kinase-2 inhibitor roscovitine and the phosphatidylinositol 3-kinase inhibitor LY294002 as negative controls. Hemicholinium-3, an inhibitor of choline transport and choline kinase activity was included as an additional control. In exponentially growing HT29 cells, geldanamycin inhibited extracellular signal-regulated kinase 1 and 2 phosphorylation in a concentration- and time-dependent manner. These changes were associated with a reduction in (methyl-
14
C)choline uptake, (methyl-
14
C) phosphocholine production and cell viability. Brief exposure to U0126, suppressed phosphocholine production to the same extent as Hemicholinium-3. In contrast to geldanamycin and U0126, which act upstream of extracellular signal-regulated kinase 1 and 2, roscovitine and LY294002 failed to suppress phosphocholine production. Our results suggest that when labelled with carbon-11 isotope, (methyl-
11
C)choline may be a useful pharmacodynamic marker for the non-invasive evaluation of geldanamycin analogues.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>12232764</pmid><doi>10.1038/sj.bjc.6600558</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2002-09, Vol.87 (7), p.783-789 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2364261 |
| source | MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Benzoquinones Biomedical and Life Sciences Biomedicine Blotting, Western Cancer Research Carbon Radioisotopes Cell Division - drug effects Cell growth Cell Survival - drug effects Choline - analogs & derivatives Choline - metabolism Choline - pharmacokinetics Cyclin-dependent kinases Drug Resistance Epidemiology Experimental Therapeutics Humans Kinases Lactams, Macrocyclic MAP Kinase Signaling System - drug effects Medical research Mitogen-Activated Protein Kinases - antagonists & inhibitors Mitogen-Activated Protein Kinases - metabolism Molecular Medicine Oncology Pharmacodynamics Phosphorylation Phosphorylation - drug effects Phosphorylcholine - metabolism Proteins Quinones - pharmacology Signal transduction Tumor Cells, Cultured |
| title | Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A08%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20radiolabelled%20choline%20as%20a%20pharmacodynamic%20marker%20for%20the%20signal%20transduction%20inhibitor%20geldanamycin&rft.jtitle=British%20journal%20of%20cancer&rft.au=Liu,%20D&rft.date=2002-09-23&rft.volume=87&rft.issue=7&rft.spage=783&rft.epage=789&rft.pages=783-789&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6600558&rft_dat=%3Cproquest_pubme%3E998023511%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230000056&rft_id=info:pmid/12232764&rfr_iscdi=true |